Concepedia

Publication | Open Access

The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance

DOIFull Paper Access

39

Citations

26

References

2016

Year

Kevin S. Quackenbush, Stacey M. Bagby, Wai Meng David Tai, Wells A. Messersmith, Anna Schreiber, Justin Greene, Jihye Kim, Guoliang Wang, Alicia Purkey, Todd M. Pitts,
Oncotarget

Abstract

Combination AZ1366 and irinotecan achieved greater anti-tumor effects compared to monotherapy. Activity was limited to CRC explants that displayed irinotecan resistance and increased protein levels of tankyrase and NuMA.

References

YearCitations

Page 1